Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
AOR vs IBB: how they differ
AOR and IBB hold 0% of their weight in the same names, and IBB returned more over the year.
iShares Core 60/40 Balanced Allocation ETF and iShares Biotechnology ETF.
What they hold in common
By the books each fund has filed, AOR and IBB hold 0% of their money in the same securities at the same weight.
| Only in AOR | Only in IBB |
|---|---|
| iShares Core S&P 500 ETF 35.07% | Vertex Pharmaceuticals, Inc. 8.09% |
| iShares Core Universal USD Bond ETF 32.09% | Amgen, Inc. 7.84% |
| iShares Core MSCI International Develope 17.02% | Gilead Sciences, Inc. 6.85% |
| iShares Core MSCI Emerging Markets ETF 7.29% | Regeneron Pharmaceuticals, Inc. 4.91% |
| iShares Core International Aggregate Bon 5.57% | Argenx SE 3.76% |
| iShares Core S&P Mid-Cap ETF 1.99% | Alnylam Pharmaceuticals, Inc. 3.12% |
| iShares Core S&P Small-Cap ETF 0.96% | Natera, Inc. 2.89% |
| Revolution Medicines, Inc. 2.78% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Jun 30, 2026.
| AOR iShares Core 60/40 Balanced Allocation ETF | IBB iShares Biotechnology ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | iShares |
| What it is | Core 60/40 Balanced Allocation | Biotechnology |
| Total return, 1 year | +11.3% | +41.5% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −6.2 pts | +24.0 pts |
| Expense ratio | 0.15% | 0.44% |
| Already in the S&P 500 | 0.0% | 35.6% |
| Holdings | 7 | 248 |
AOR in plain words
AOR is an index equity fund tracking the Core 60/40 Balanced Allocation. Over the year to Sep 11, 2026 it returned +11.3% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.15% a year. By its holdings filed for Apr 30, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 7 positions, with the top ten at 100.0%.
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, AOR or IBB?
- In the year to Sep 12, 2026, with distributions reinvested, AOR returned +11.3% and IBB returned +41.5%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, AOR or IBB?
- AOR charges 0.15% a year and IBB charges 0.44%, so AOR is cheaper. Fees come from each fund's prospectus.
- How much do AOR and IBB overlap with the S&P 500?
- By their latest filed holdings, 0% of AOR and 36% of IBB by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, AOR against IBB, data as of Sep 12, 2026. https://etfiq.com/compare/any/AOR-IBB Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources